Cell Bio Human TechLtd Past Earnings Performance

Past criteria checks 2/6

Cell Bio Human TechLtd's earnings have been declining at an average annual rate of -52.3%, while the Chemicals industry saw earnings growing at 7.8% annually. Revenues have been declining at an average rate of 0.2% per year. Cell Bio Human TechLtd's return on equity is 3.1%, and it has net margins of 5.1%.

Key information

-52.3%

Earnings growth rate

-51.0%

EPS growth rate

Chemicals Industry Growth	13.9%
Revenue growth rate	-0.2%
Return on equity	3.1%
Net Margin	5.1%
Last Earnings Update	30 Sep 2024

Recent past performance updates

No updates

Recent updates

Cell Bio Human Tech Co.,Ltd's (KOSDAQ:318160) Share Price Is Matching Sentiment Around Its Revenues

Dec 15

Revenue & Expenses Breakdown

How Cell Bio Human TechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A318160 Revenue, expenses and earnings (KRW Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	27,817	1,413	3,803	498
30 Jun 24	27,836	72	3,856	528
31 Mar 24	27,968	-1,709	3,634	572
31 Dec 23	27,324	-1,857	3,594	657
30 Sep 23	26,254	-902	3,466	472
30 Jun 23	27,332	994	3,212	619
31 Mar 23	27,092	3,010	3,106	690
31 Dec 22	27,545	2,890	3,088	742
30 Sep 22	28,112	2,564	3,051	990
30 Jun 22	27,080	-144	3,348	876
31 Mar 22	30,492	1,565	3,514	801
31 Dec 21	35,161	3,131	3,632	718
31 Dec 20	28,588	3,776	3,793	467
31 Dec 19	24,103	4,062	3,572	246
31 Dec 18	27,570	9,009	2,243	203
31 Dec 17	18,583	5,159	1,522	346

Quality Earnings: A318160 has high quality earnings.

Growing Profit Margin: A318160 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A318160's earnings have declined by 52.3% per year over the past 5 years.

Accelerating Growth: A318160 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A318160 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (21%).

Return on Equity

High ROE: A318160's Return on Equity (3.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 21:37
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cell Bio Human Tech Co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution